BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12234993)

  • 1. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts.
    Mellinghoff IK; Tran C; Sawyers CL
    Cancer Res; 2002 Sep; 62(18):5254-9. PubMed ID: 12234993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
    Kim SJ; Uehara H; Karashima T; Shepherd DL; Killion JJ; Fidler IJ
    Clin Cancer Res; 2003 Mar; 9(3):1200-10. PubMed ID: 12631626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.
    Weber KL; Doucet M; Price JE; Baker C; Kim SJ; Fidler IJ
    Cancer Res; 2003 Jun; 63(11):2940-7. PubMed ID: 12782601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
    Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
    Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.
    Craft N; Shostak Y; Carey M; Sawyers CL
    Nat Med; 1999 Mar; 5(3):280-5. PubMed ID: 10086382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T; Lin FF; Rao P; Lin MF
    Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.
    Nagasawa J; Mizokami A; Koshida K; Yoshida S; Naito K; Namiki M
    Int J Urol; 2006 May; 13(5):587-92. PubMed ID: 16771730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
    Chu I; Blackwell K; Chen S; Slingerland J
    Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer.
    Mendoza N; Phillips GL; Silva J; Schwall R; Wickramasinghe D
    Cancer Res; 2002 Oct; 62(19):5485-8. PubMed ID: 12359757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells.
    Meng TC; Lee MS; Lin MF
    Oncogene; 2000 May; 19(22):2664-77. PubMed ID: 10851066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
    Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002.
    Tørring N; Dagnaes-Hansen F; Sørensen BS; Nexø E; Hynes NE
    Prostate; 2003 Jul; 56(2):142-9. PubMed ID: 12746839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
    Chiu FL; Lin JK
    Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
    Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
    Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents.
    Brandt R; Wong AM; Hynes NE
    Oncogene; 2001 Sep; 20(39):5459-65. PubMed ID: 11571643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R).
    Ling MT; Wang X; Lee DT; Tam PC; Tsao SW; Wong YC
    Carcinogenesis; 2004 Apr; 25(4):517-25. PubMed ID: 14688027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer.
    Veeramani S; Yuan TC; Chen SJ; Lin FF; Petersen JE; Shaheduzzaman S; Srivastava S; MacDonald RG; Lin MF
    Endocr Relat Cancer; 2005 Dec; 12(4):805-22. PubMed ID: 16322323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice.
    Yazici S; Kim SJ; Busby JE; He J; Thaker P; Yokoi K; Fan D; Fidler IJ
    Prostate; 2005 Nov; 65(3):203-15. PubMed ID: 15948138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.